JYSELECA is a second generation, once-daily, oral JAK inhibitor1,2

JAK1-preferential inhibition

  • Proinflammatory cytokine signalling via JAK1-containing protein complexes has been implicated in UC pathogenesis3,4
  • In human cellular assays, JYSELECA preferentially inhibited JAK1/JAK3, JAK1/JAK2, and JAK1/TYK2 mediated signalling, with functional selectivity over cytokine receptors that signal via pairs of JAK2 or JAK2/TYK25

JYSELECA is a JAK1-preferential inhibitor with more than five-fold higher potency for JAK1 over other JAK isoforms, as measured in biochemical assays


EPO, erythropoietin; GH, growth hormone; GM-CSF, granulocyte-macrophage colony stimulating factor; IFN, interferon; IL, interleukin; JAK, Janus kinase; TPO, thrombopoietin; TYK, tyrosine kinase.

References: 1. Danese S, Argollo M, Le Berre C, et al. Gut 2019;68:1893–1899. 2. Salas A, Hernandez-Rocha C, Duijvestein M, et al. Nat Rev Gastroenterol Hepatol 2020;17:323–337. 3. Schwartz DM, Kanno Y, Villarino A, et al. Nat Rev Drug Discov 2017;17:78. 4. Virtanen AT, Haikarainen T, Raivola J, et al. BioDrugs 2019;33:15–32. 5. Galien R, Vayssiere B, de Vos S, et al. Arthritis Rheum 2013;65 Suppl 10:Abstract 478.